OTCMKTS:NVZMY - NOVOZYMES A/S/S Stock Price, Forecast & News

NOVOZYMES A/S/S trades on the OTCMKTS under the ticker symbol "NVZMY."

NOVOZYMES A/S/S announced an annual dividend on Friday, January 24th. Investors of record on Friday, February 28th will be given a dividend of $0.517 per share on Tuesday, March 17th. This represents a yield of 1.01%. The ex-dividend date is Thursday, February 27th. This is a boost from NOVOZYMES A/S/S's previous annual dividend of $0.50. View NOVOZYMES A/S/S's Dividend History.

NOVOZYMES A/S/S is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for NOVOZYMES A/S/S.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NOVOZYMES A/S/S in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NOVOZYMES A/S/S.

Press coverage about NVZMY stock has been trending somewhat negative recently, InfoTrie reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NOVOZYMES A/S/S earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for NOVOZYMES A/S/S.

Some companies that are related to NOVOZYMES A/S/S include Biogen (BIIB), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), Acceleron Pharma (XLRN), China Biologic Products (CBPO), Repligen (RGEN), Spark Therapeutics (ONCE), bluebird bio (BLUE), Adaptive Biotechnologies (ADPT) and Ablynx (ABLYF).

Based on aggregate information from My MarketBeat watchlists, some companies that other NOVOZYMES A/S/S investors own include ManpowerGroup (MAN), TeamHealth (TMH), Novo Nordisk A/S (NVO), FOX (FOXA), Level One Bancorp (LEVL), Duke Energy (DUK), Emerson Electric (EMR), AT&T (T), Zayo Group (ZAYO) and DANSKE BK A/S/S (DNKEY).

Shares of NVZMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVZMY stock can currently be purchased for approximately $52.18.

NOVOZYMES A/S/S has a market capitalization of $15.50 billion and generates $2.28 billion in revenue each year. The biotechnology company earns $511 million in net income (profit) each year or $1.75 on an earnings per share basis. NOVOZYMES A/S/S employs 6,427 workers across the globe.View Additional Information About NOVOZYMES A/S/S.

The official website for NOVOZYMES A/S/S is http://www.novozymes.com/.

NOVOZYMES A/S/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The biotechnology company can be reached via phone at 45-4446-0000 or via email at [email protected]